Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a multi-component injectable pharmaceutical kit containing bupivacaine hydrochloride, lidocaine hydrochloride, methylprednisolone acetate, and isopropyl alcohol. Bupivacaine and lidocaine are amide-type local anesthetics that block sodium channels in neuronal membranes to inhibit nerve impulse conduction, providing local or regional anesthesia and analgesia. Methylprednisolone acetate is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressive properties; it acts by binding to the glucocorticoid receptor to modulate gene expression and suppress inflammatory mediators. Isopropyl alcohol serves as an antiseptic component in the formulation. This combination is used for intra-articular, intralesional, intramuscular, soft tissue injection or topical application for pain management (including postsurgical analgesia), inflammation control (such as in arthritis), or other conditions requiring both local anesthesia and corticosteroid effect[5][1][2]. The product may also contain additional excipients such as povidone-iodine and sodium chloride depending on the specific kit.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bupivacaine + lidocaine + methylprednisolone acetate + alcohol.